Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2011, vol. 20, nr 4, July-August, p. 423–429

Publication type: original article

Language: English

Association of Interleukin 1β Gene and Interleukin 1 Receptor Antagonist Gene Polymorphisms and Gastric Cancer Risk

Związek między polimorfizmami genu interleukiny 1β i genu antagonisty receptora interleukiny 1 i zagrożenie rozwojem raka żołądka

Florin Burada1,, Florin Burada2,, Cristina Angelescu3,, Cristina Angelescu2,, Mihai Ioana3,, Mihai Ioana2,, Anca-Lelia Riza1,, Paul Mitrut4,, Robert Dinu3,, Emil Moraru5,, Francisc Mixich3,, Francisc Mixich2,, Mihai Cruce3,, Adrian Saftoiu2,

1 Department of Medical Genetics, University of Medicine and Pharmacy, Craiova, Romania

2 Research Center in Gastroenterology and Hepatology, Craiova, Romania

3 Department of Molecular and Cellular Biology, University of Medicine and Pharmacy, Craiova, Romania

4 Department of Medical Semiology, University of Medicine and Pharmacy, Craiova, Romania

5 Department of General Surgery, Emergency Hospital of Craiova, Romania

Abstract

Background. Gastric cancer is the second leading cause of cancer death in both sexes worldwide and the prognosis of this malignancy remains very poor. Objectives,
Material and Methods. This study assesses the association between interleukin 1β gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms and gastric cancer susceptibility in the Romanian population. The authors investigated IL-1B –31T > C, IL-1B +3954C > T and IL1-RN +2018T > C polymorphisms in 103 subjects diagnosed with gastric cancer and 244 healthy controls. These polymorphisms were genotyped by allelic discrimination TaqMan PCR.
Results. In all gastric cancer cases, a significant association with an increased risk of gastric cancer was only observed for the IL1-RN +2018T > C polymorphism (OR 2.52, 95% CI: 1.06–6.01). A stratified analysis showed that IL1-RN +2018T > C was associated with an increased risk of gastric non-cardia adenocarcinoma (OR 2.77, 95% CI: 1.10–6.99) and intestinal type (OR 3.08, 95% CI: 1.17–8.11). The authors found no significant differences between gastric cancer cases and controls for IL1-B –31CC (OR 0.77, 95% CI: 0.32–1.84) and IL1-B +3954TT (OR 0.77, 95% CI:0.32–1.85) genotypes polymorphisms.
Conclusion. The results presented do not support the hypothesis that the IL-1B –31T > C and IL-1B +3954C > > T polymorphisms determine differences in gastric cancer risk among different individuals, but the IL1-RN +2018T > C polymorphism could contribute to gastric cancer risk in the Romanian population.

Streszczenie

Wprowadzenie. Rak żołądka jest drugą pod względem częstości przyczyną zgonów z powodu nowotworów u obu płci na całym świecie, a rokowanie nadal jest bardzo złe. Cel pracy, materiał i metody. Ocena związku między polimorfizmami genu interleukiny 1β (IL-1B) i genu antagonisty receptora interleukiny 1 (IL-1RN) a podatnością na raka w populacji Rumunii. Autorzy badali polimorfizmy IL-1B-31T > C, IL-1B +3954 C > T i IL1-RN +2018 T > C u 103 pacjentów z rozpoznanym rakiem żołądka i 244 zdrowych. Polimorfizmy genotypowano przeprowadzone metodą dyskryminacji alleli z użyciem sond TaqMan PCR.
Wyniki. We wszystkich przypadkach raka żołądka istotny związek ze zwiększonym ryzykiem tego raka obserwowano jedynie dla polimorfizmu IL1-RN +2018 T > C (OR 2,52, 95% CI: 1.06–6.01). Analiza warstwowa wykazała, że IL1-RN +2018 T > C wiązał się ze zwiększonym ryzykiem gruczolakoraka żołądka (OR 2,77, 95% CI: 1.10–6 0.99) i jelit (OR 3,08, 95% CI: 1.17–8 0.11). Autorzy nie stwierdzili istotnych różnic między przypadkami raka żołądka a grupą kontrolną dla polimorfizmów genotypów IL1-B-31CC (OR 0,77, 95% CI: 0.32-1 0.84) i IL1-B +3954 TT (OR 0,77, 95% CI: 0.32–1 0.85).
Wnioski. Przedstawione wyniki nie potwierdzają hipotezy, że polimorfizmy IL-1B-31T > C i IL-1B +3954 C > T określają różnice w ryzyku rozwoju raka żołądka wśród różnych osób, ale polimorfizm IL1-RN +2018 T > C może wpływać na zwiększone ryzyko raka żołądka w populacji Rumunii.

Key words

gastric cancer, interleukin, gene polymorphism, genotype, risk

Słowa kluczowe

rak żołądka, interleukina, polimorfizm genu, genotyp, ryzyko

References (22)

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127, 2893–2917.
  2. Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46, 765–781.
  3. Buffart TE, Carvalho B, Mons T, Reis RM, Moutinho C, Silva P, van Grieken NC, Vieth M, Stolte M, van de Velde CJ, Schrock E, Matthaei A, Ylstra B, Carneiro F, Meijer GA: DNA copy number profiles of gastric cancer precursor lesions. BMC Genomics 2007, 1, 8, 345.
  4. González CA, Sala N, Capellá G: Genetic susceptibility and gastric cancer risk. Int J Cancer 2002, 100, 249–260.
  5. Nicklin MJ, Weith A, Duff GW: A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 1994, 19, 382–384.
  6. Arend WP, Malyak M, Guthridge CJ, Gabay C: Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998, 16, 27–55.
  7. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993, 91, 403–404.
  8. Crusius JB, Canzian F, Capellá G, Peña AS, Pera G, Sala N, Agudo A, Rico F, Del Giudice G, Palli D, Plebani M, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Pala V, Save VE, Vineis P, Tumino R, Panico S, Berglund G, Manjer J, Stenling R, Hallmans G, Martínez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key TJ, Binghan S, Caldas C, Linseisen J, Kaaks R, Overvad K, Tjønneland A, Büchner FC, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Lund E, Jenab M, Rinaldi S, Ferrari
  9. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404, 398–402.
  10. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS: The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature 2001, 412, 99.
  11. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L, Sicotte H, Staats B, Acharya M, Crenshaw A, Eckert A, Puri V, Gerhard DS, Chanock SJ: SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006, 34, D617– 621.
  12. Kamangar F, Cheng C, Abnet CC, Rabkin CS: Interleukin-1B polymorphisms and gastric cancer risk-a metaanalysis. Cancer Epidemiol Biomarkers Prev 2006, 15, 1920–1928.
  13. Camargo MC, Mera R, Correa P, Peek RM Jr, Fontham ET, Goodman KJ, Piazuelo MB, Sicinschi L, Zabaleta J, Schneider BG: Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006, 15, 1674–1687.
  14. Wang P, Xia HH, Zhang JY, Dai LP, Xu XQ, Wang KJ: Association of interleukin-1 gene polymorphisms with gastric cancer: a meta-analysis. Int J Cancer 2007, 120, 552–562.
  15. Sugimoto M, Furuta T, Shirai N, Nakamura A, Xiao F, Kajimura M, Sugimura H, Hishida A: Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 beta on development of peptic ulcer and gastric cancer. J Gastroenterol Hepatol 2007, 22, 51–59.
  16. Lee SG, Kim B, Choi W, Lee I, Choi J, Song K: Lack of association between pro-inflammatory genotypes of the interleukin-1 (IL-1B –31 C/+ and IL-1RN *2/*2) and gastric cancer/duodenal ulcer in Korean population. Cytokine 2003, 21, 167–171.
  17. García-González MA, Lanas A, Quintero E, Nicolás D, Parra-Blanco A, Strunk M, Benito R, Angel Simón M, Santolaria S, Sopeña F, Piazuelo E, Jiménez P, Pascual C, Mas E, Irún P, Espinel J, Campo R, Manzano M, Geijo F, Pellisé M, González-Huix F, Nieto M, Espinós J, Titó L, Bujanda L, Zaballa M; Spanish Gastroenterological Association AEG: Gastric cancer susceptibility is not linked to pro-and anti-inflammatory cytokine gene polymorphisms in whites: a nation wide multicenter study in Spain. Am J Ga
  18. Ruzzo A, Graziano F, Pizzagalli F, Santini D, Battistelli V, Panunzi S, Canestrari E, Catalano V, Humar B, Ficarelli R, Bearzi I, Cascinu S, Naldi N, Testa E, Magnani M: Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. Ann Oncol 2005, 16, 887–892.
  19. Zambon CF, Basso D, Navaglia F, Belluco C, Falda A, Fogar P, Greco E, Gallo N, Rugge M, Di Mario F, Plebani M: Proand anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine 2005, 29, 141–152.
  20. Hurme M, Santtila S: IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998, 28, 2598–2602.
  21. Garza-González E, Bosques-Padilla FJ, El-Omar E, Hold G, Tijerina-Menchaca R, Maldonado-Garza HJ, Pérez-Pérez GI: Role of the polymorphic IL-1B, IL-1RN and TNF-A genes in distal gastric cancer in Mexico. Int J Cancer 2005, 114, 237–241.
  22. Alpízar-Alpízar W, Pérez-Pérez GI, Une C, Cuenca P, Sierra R: Association of interleukin-1B and interleukin1RN polymorphisms with gastric cancer in a high-risk population of Costa Rica. Clin Exp Med 2005, 5, 169–176.